For HER2-positive metastatic disease, we adopted fam-trastuzumab deruxtecan (Enhertu), whose superiority over T-DM1 was established in DESTINY-Breast 03 [progression-free survival (PFS) HR: 0.28; OS HR: 0.55] [26,27]. Here, ERBB2 is linked to metastatic neoplasm.